Clinical trial

A Study of Ocrelizumab Administered Subcutaneously in Participants With Multiple Sclerosis Who Switch From an Approved Anti-CD20 Therapy

NCT07609719

Study summary

ClinicalTrials.gov

A Study of Ocrelizumab Administered Subcutaneously in Participants With Multiple Sclerosis Who Switch From an Approved Anti-CD20 Therapy

Design: INTERVENTIONAL · Status: RECRUITING · Phase: PHASE4

Loading study purpose, treatment groups and outcomes…

View the complete registry record, eligibility and contacts at ClinicalTrials.gov

Drugs and interventions used in this trial

1 registered

These interventions are listed by ClinicalTrials.gov. An RxNorm link indicates a mapped medicine record; the registry name alone is not proof of a specific branded formulation.

DRUG · Unmapped registry intervention OCR SC Find medicine records · Find other trials using this name

StatusRECRUITING

Study typeINTERVENTIONAL

Start date2026-09-02

PhasePHASE4

Conditions

Multiple Sclerosisverified · MONDO: multiple sclerosis

Interventions

OCR SCDRUG

Sponsors & collaborators

Genentech, Inc.lead sponsor

Mapped research locations

AtlantaGeorgia, United States1 ScottsdaleArizona, United States1 MaitlandFlorida, United States1 CordovaTennessee, United States1 GuaynaboPuerto Rico1

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT07609719 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.